Page 17 - ேசை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer s Disease, Insomnia and Epilepsy Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer s disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome News provided by Share this article Share this article WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company s deep neurology pipeline and portfolio, including Alzheimer s disease, insomnia and epilepsy, will be presented at the 73 rd Annual Meeting of the American Academy of Neurology (AAN), taking place virtually from April 17-22, 2021.

United statesNew jerseyNorth carolinaGary zammitShau yu lynchAlzheimers dementRyan husniGenevieve meierCarmen castrillo vigueraCraig chepkeIvan cheungChris vancheriMichael irizarryRussell rosenbergRakeh jainRohit shankar